Equities
Health CareMedical Equipment and Services
  • Price (USD)144.55
  • Today's Change-10.02 / -6.48%
  • Shares traded1.52m
  • 1 Year change-24.26%
  • Beta1.2968
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

  • Revenue in USD (TTM)8.10bn
  • Net income in USD599.48m
  • Incorporated1989
  • Employees39.80k
  • Location
    ICON PLCSouth County Business ParkLEOPARDSTOWN, Dublin 18DUBLIN 00000IrelandIRL
  • Phone+353 12912000
  • Fax+353 12912700
  • Websitehttps://www.iconplc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vaxcyte Inc0.00-657.20m7.84bn414.00--2.50-----4.84-4.840.0022.250.00----0.00-19.53-26.00-20.51-27.91------------0.00-------15.33--151.05--
Nuvalent Inc0.00-381.44m7.95bn218.00--8.80-----5.32-5.320.0011.700.00----0.00-35.18-25.32-37.61-26.51------------0.00-------106.59------
Praxis Precision Medicines Inc7.46m-273.04m8.76bn116.00--19.69--1,173.48-12.90-12.900.353316.230.0184----64,336.21-67.20-70.37-75.12-79.85-----3,658.53-6,809.15----0.00--249.53---48.30------
Arrowhead Pharmaceuticals Inc1.09bn202.27m8.77bn711.0040.6515.1433.918.041.541.547.904.140.8335--9.861,534,432.0017.84-25.9621.44-30.82----21.41-76.01--5.910.5068--23,258.1556.6399.73--13.66--
Charles River Lbrtrs ntrntl Inc4.02bn-83.48m9.14bn18.60k--2.6826.302.27-1.56-1.5680.1869.200.51868.235.41216,328.20-1.035.12-1.206.0134.6836.56-1.989.471.103.180.3880.00-1.929.09-97.83-47.2510.64--
Tempus AI Inc1.11bn-203.88m10.16bn2.40k--20.00--9.19-1.18-1.186.452.860.67959.295.15460,524.20-12.53-53.69-15.38-72.1061.7345.68-18.45-84.293.12-3.830.7104--30.3862.05-180.61--5.36--
BIO-TECHNE Corp1.22bn79.96m10.24bn3.10k129.015.0855.768.430.50760.50767.7412.900.46822.066.04392,121.603.087.623.278.1366.6067.496.5816.743.0856.920.114526.725.2310.55-56.35-20.37-9.74-4.36
Madrigal Pharmaceuticals Inc740.64m-289.13m11.09bn528.00--17.72--14.97-13.01-13.0133.3927.560.60820.900810.301,402,727.00-23.74-68.48-30.98-85.3295.25---39.04-876.553.26--0.3519-------24.69--106.52--
Summit Therapeutics Inc0.00-921.62m11.14bn159.00--57.96-----1.24-1.240.000.25830.00----0.00-241.08-78.31-287.72-86.84-------31,307.77----0.00------64.01---16.43--
Exelixis Inc2.29bn677.90m11.78bn1.15k18.505.4516.655.152.382.388.008.060.79133.197.901,994,959.0023.449.5127.0310.7796.6396.3229.6315.613.68--0.000.0018.4917.51150.8910.1817.25--
ICON PLC8.10bn599.48m11.80bn39.80k20.891.2611.941.467.407.40101.04122.250.4806--3.00193,379.503.563.704.334.4628.1529.007.407.41--5.940.2675--1.9924.1729.2616.1827.11--
Regencell Bioscience Holdings Ltd0.00-3.58m13.70bn12.00--2,819.75-----0.0073-0.00730.000.00980.00----0.00-50.50-53.93-53.75-65.67------------0.00------16.68--5.32--
Ionis Pharmaceuticals Inc966.96m-256.34m13.73bn1.07k--22.11--14.20-1.71-1.715.873.840.31630.605445.47904,542.60-8.39-11.71-10.45-13.7298.7898.42-26.51-44.152.78--0.7414---10.48-8.88-23.92--7.94--
Medpace Holdings Inc2.53bn451.12m14.94bn6.20k34.6832.7031.175.9015.2915.2985.6816.221.24--7.24--22.1318.5255.4237.5330.0629.6017.8317.15--------19.9722.2711.5725.500.0102--
Data as of Feb 10 2026. Currency figures normalised to ICON PLC's reporting currency: US Dollar USD

Institutional shareholders

40.89%Per cent of shares held by top holders
HolderShares% Held
Artisan Partners LPas of 30 Sep 20257.07m9.26%
Orbis Investment Management Ltd.as of 30 Sep 20254.14m5.42%
Wellington Management Co. LLPas of 30 Sep 20253.65m4.78%
Principal Global Investors LLCas of 31 Dec 20253.00m3.93%
Ninety One UK Ltd.as of 31 Dec 20252.95m3.86%
Invesco Advisers, Inc.as of 30 Sep 20252.83m3.71%
Harris Associates LPas of 30 Sep 20252.34m3.07%
Templeton Global Advisors Ltd.as of 30 Sep 20251.88m2.46%
Ruane, Cunniff & Goldfarb LPas of 30 Sep 20251.70m2.23%
Massachusetts Financial Services Co.as of 31 Dec 20251.66m2.17%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.